ATE355297T1 - Tgf-beta inhibitoren und methoden - Google Patents

Tgf-beta inhibitoren und methoden

Info

Publication number
ATE355297T1
ATE355297T1 AT01977301T AT01977301T ATE355297T1 AT E355297 T1 ATE355297 T1 AT E355297T1 AT 01977301 T AT01977301 T AT 01977301T AT 01977301 T AT01977301 T AT 01977301T AT E355297 T1 ATE355297 T1 AT E355297T1
Authority
AT
Austria
Prior art keywords
tgf
methods
beta inhibitors
methylalanine
formula
Prior art date
Application number
AT01977301T
Other languages
English (en)
Inventor
Rajendra S Bhatnagar
Craig A Gough
Jing Jing Qian
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE355297T1 publication Critical patent/ATE355297T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT01977301T 2000-09-29 2001-09-27 Tgf-beta inhibitoren und methoden ATE355297T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/676,108 US6509318B1 (en) 2000-09-29 2000-09-29 TGF-B inhibitors and methods

Publications (1)

Publication Number Publication Date
ATE355297T1 true ATE355297T1 (de) 2006-03-15

Family

ID=24713258

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01977301T ATE355297T1 (de) 2000-09-29 2001-09-27 Tgf-beta inhibitoren und methoden

Country Status (9)

Country Link
US (2) US6509318B1 (de)
EP (1) EP1320541B1 (de)
JP (1) JP2004509931A (de)
AT (1) ATE355297T1 (de)
AU (1) AU2001296431A1 (de)
CA (1) CA2421851A1 (de)
DE (1) DE60126966T2 (de)
ES (1) ES2282301T3 (de)
WO (1) WO2002026935A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509318B1 (en) * 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
GB0217136D0 (en) * 2002-07-24 2002-09-04 Renovo Ltd Wound healing & treatment of fibrosis
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
US20060293227A1 (en) * 2005-06-24 2006-12-28 Bhatnagar Rajendra S Cosmetic compositions and methods using transforming growth factor-beta mimics
US20060293228A1 (en) * 2005-06-24 2006-12-28 Bhatnagar Rajendra S Therapeutic compositions and methods using transforming growth factor-beta mimics
ES2621161T3 (es) 2007-07-31 2017-07-03 The Board Of Regents Of The University Of Texas System Familia de micro-ARN que modula la fibrosis y usos de la misma
WO2010088778A1 (en) * 2009-02-09 2010-08-12 The Royal Institution For The Advancement Of Learning/Mcgill University Cd109 polypeptides and uses thereof for the treatment of skin cells
DK2970890T3 (da) 2013-03-14 2020-05-04 Brigham & Womens Hospital Inc Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
CA2999711A1 (en) 2014-09-26 2016-03-31 Rajendra Sahai Bhatnagar Inhibitors of nf kappa-b activity for treatment of diseases and disorders
EP3313420B1 (de) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Verfahren und zusammensetzungen in bezug auf hämatopoetische stammzellenexpansion, -anreicherung und -pflege
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
MX390321B (es) 2016-12-30 2025-03-20 Frequency Therapeutics Inc Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
AU2019240065A1 (en) 2018-03-20 2020-09-24 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2019236766A1 (en) 2018-06-06 2019-12-12 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
JP2021533788A (ja) 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法
CA3124700A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2020227738A1 (en) * 2019-05-09 2020-11-12 The University Of Chicago Novel material for skin wound closure and scar prevention
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106678D0 (en) 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
WO1993019783A1 (en) 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
JP4083794B2 (ja) 1994-03-29 2008-04-30 レノボ・リミテッド 創傷の治癒
US6638912B2 (en) * 1995-05-01 2003-10-28 The Regents Of The University Of California Peptide compositions mimicking TGF-β activity
US5780436A (en) 1995-05-01 1998-07-14 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US5661127A (en) * 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
JP3279940B2 (ja) 1996-11-27 2002-04-30 シャープ株式会社 電子回路装置の製造方法、半田残渣均一化治具、金属ロウペースト転写用治具及び電子回路装置の製造装置
US6509318B1 (en) * 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods

Also Published As

Publication number Publication date
US6509318B1 (en) 2003-01-21
JP2004509931A (ja) 2004-04-02
EP1320541A4 (de) 2005-01-12
ES2282301T3 (es) 2007-10-16
DE60126966D1 (de) 2007-04-12
US20030083265A1 (en) 2003-05-01
WO2002026935A2 (en) 2002-04-04
EP1320541B1 (de) 2007-02-28
EP1320541A2 (de) 2003-06-25
DE60126966T2 (de) 2008-04-10
WO2002026935A3 (en) 2002-06-27
AU2001296431A1 (en) 2002-04-08
CA2421851A1 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
DE60126966D1 (de) Tgf-beta inhibitoren und methoden
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
SE0002202D0 (sv) New peptides
EP1801206A4 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
JP3318622B2 (ja) プロリルエンドペプチダーゼ阻害剤
BR0012418A (pt) Derivados de peptìdeo cìclicos como inibidores de integrina alfavbeta6
FR2846883B1 (fr) Composition cosmetique comprenant, comme ingredient actif, au moins un peptide et utilisation de ce peptide
CY1107990T1 (el) Τριπεπτιδια και παραγωγα τριπεπτιδιων για τη θepαπεια νευροεκφυλιστικων ασθενειων
BR0310003A (pt) compostos peptìdeos e seu uso como substratos de protease
WO2004099240B1 (en) Peptides and mixtures thereof for use in the detection of severe acute respiratory syndrome-associated coronavirus (sars)
LV10108A (lv) Sunu proliferacijas inhibitori farmaceitiska kompozicija savienojumu iegusanas metode sunu proliferacijas inhibesanas panemieni
FR2861731B1 (fr) Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
CA2549185A1 (en) Peptide inhibiting angiotensin converting enzyme
ATE447025T1 (de) Ionenkanalaktivität hemmende niedrigmolekulare peptide
EA200701727A1 (ru) Связанные с матрицей бета-шпилечные пептидомиметики с ингибирующей активностью в отношении протеаз
ATE42308T1 (de) Pharmakologisch aktive peptide.
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
AU2003264679A8 (en) Peptides having antimicrobial properties and compositions containing same in particular for preserving foods
EP2431029A3 (de) Verfahren zur Hemmung von Prostatakrebszellproliferation
DK0833848T3 (da) Faktor IX-bindende peptider afledt af faktor VIII og anvendelse heraf som inhibitorer af blodkoagulation
ATE453399T1 (de) Isolierte dipeptide mit ace-inhibitionseffekt
PT1363656E (pt) Tripeptideos e derivados de tripeptideos para o tratamento de doencas pos-lesionais do sistema nervoso
DK1960515T3 (da) Inflammationshæmmende peptider
WO2005072766A3 (en) Peptides that bind to hsp90 proteins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1320541

Country of ref document: EP

REN Ceased due to non-payment of the annual fee